Quanterix Corporation

NASDAQ:QTRX

Medical - Devices

Healthcare
$2.07 +15.80%

+$0.46 today

Market cap
$98.28M
Beta
1.12
P/E (TTM)
-1.5
EPS (TTM)
-$2.22
52W Low $2.40High $8.77

Volume 3.54M

Average 1.15M

QTRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Quanterix CorporationNASDAQ: QTRX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $7.32M fell 27.0% year over year, behind the -3.4% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Research & development amounted to 25.9% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.0% toward the trailing-twelve-month pace of -3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.32M-16.7% QoQ
Last fiscal yearDec 2025
$35.92M+15.6% YoY
LTMMar 2026
$33.21M-3.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.0%——
1 year+15.6%——
3-year CAGR+10.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
35.92M USD
Year-over-year change
+15.6%
4-year CAGR
+6.1%

Research & Development vs competitors

How QTRX compares with its peers on the latest reported figures

  • QTRX's LTM Mar 2026 research & development of $33.21M is the 2nd highest of the 11 companies compared; the peer median is $16.6M.
  • Its year-over-year change of -3.4% is the 5th highest of 11, against a peer median of -7.4%.
  • Research & development amounts to 22.9% of revenue for QTRX, versus a peer median of 18.1%.
QTRX Competitors Peer median
Research & Development for QTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
QTRXQuanterix CorporationLTM Mar 2026$33.21M -3.4%+10.2%22.9%
SENSSenseonics Holdings, Inc.LTM Mar 2026$32.9M -13.4%-7.3%80.8%
OMOutset Medical, Inc.LTM Mar 2026$21.34M -31.8%-24.3%18.1%
INGNInogen, Inc.LTM Mar 2026$20.46M +7.3%-4.0%5.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025$19.24M -4.7%-10.1%147.7%
MASS908 Devices Inc.LTM Mar 2026$13.97M -23.1%-7.7%24.2%
SGHTSight Sciences, Inc.LTM Mar 2026$12.72M -28.5%-13.9%16.0%
CVRXCVRx, Inc.LTM Mar 2026$11.7M +10.5%+3.8%19.8%
VMDViemed Healthcare, Inc.LTM Mar 2026$2.8M -10.1%+3.8%1.0%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$1.81M +151.4%+33.6%4.1%
Peer median (excluding QTRX) $16.6M-7.4%-5.7%18.1%

Competitors are the stored peer set for QTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.56M105.52M121.14M135.44M138.65M
Cost of Revenue45.78M60.16M48.14M54.32M73.94M
Gross Profit64.77M45.36M73M81.12M64.72M
Gross Margin58.6%43.0%60.3%59.9%46.7%
Research & Development28.38M26.81M26.06M31.08M35.92M
Selling, General & Admin92.91M91.85M92.82M104.64M138.85M
Operating Expenses121.29M149.63M118.99M133.74M174.53M
Depreciation & Amortization4.88M5.41M8.29M8.36M18.93M
EBITDA(50.3M)(67.89M)(36.37M)(29.74M)(93.35M)
EBITDA Margin-45.5%-64.3%-30.0%-22.0%-67.3%
Operating Income(56.52M)(104.26M)(45.99M)(52.62M)(109.82M)
Operating Margin-51.1%-98.8%-38.0%-38.8%-79.2%
Interest Income05.13M15.84M14.66M8.57M
Interest Expense403K0000
Other Income / Expenses937K4.85M18.36M14.52M(2.46M)
Income Before Tax(55.58M)(99.41M)(27.64M)(38.1M)(112.27M)
Pre-Tax Margin-50.3%-94.2%-22.8%-28.1%-81.0%
Income Tax Expense(36K)164K719K434K(5.12M)
Net Income(55.55M)(99.57M)(28.35M)(38.53M)(107.15M)
Net Margin-50.2%-94.4%-23.4%-28.4%-77.3%
EPS (Basic)(1.60)(2.61)(0.86)(1.00)(2.51)
EPS (Diluted)(1.60)(2.61)(0.86)(1.00)(2.51)
Weighted Avg Shares36M36.99M37.59M38.37M42.64M
Weighted Avg Shares (Diluted)36M36.99M37.59M38.37M42.64M

Quanterix Corporation

NASDAQ:QTRX

Intrinsic Alpha fair value

Locked

Current Price

$2.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.